GLP-1 Medications and Addiction: Alcohol, Nicotine, and Opioid Use Disorder Research

Do GLP-1 medications reduce alcohol, nicotine, and drug cravings? ATTAIN-1 trial results, nucleus accumbens mechanism, and what the research shows for substance use disorder. April 2026.

Sarah ChenLead Health Editor

Updated April 15, 2026

6 questions

Quick Answers

Click any question to expand the answer

Emerging evidence — primarily from preclinical studies and Phase 2 trials — suggests GLP-1 medications meaningfully reduce alcohol cravings and consumption, with preliminary signals for nicotine and opioids. The ATTAIN-1 Phase 2 trial (semaglutide for alcohol use disorder, 2025) showed statistically significant reductions in heavy drinking days and alcohol consumption. The mechanism is the same pathway that reduces food cravings: GLP-1 receptors in the nucleus accumbens and ventral tegmental area modulate dopaminergic reward signaling — which underlies both food reward and substance reward. 'Food noise' reduction and addiction craving reduction appear to share a common neural mechanism.

ATTAIN-1 (published 2025) was a Phase 2 randomized controlled trial of semaglutide in adults with alcohol use disorder (AUD). Key findings: (1) Significant reduction in heavy drinking days (defined as ≥4 drinks for women, ≥5 for men) vs placebo; (2) Reduction in total weekly alcohol consumption; (3) Effect size was meaningful but not curative — semaglutide reduced alcohol use; it did not eliminate it; (4) Effects were seen across the range of AUD severity; (5) Side effect profile was consistent with weight loss trials — primarily GI. This trial is the first large Phase 2 evidence for GLP-1 in AUD specifically, building on substantial preclinical data showing GLP-1 reduces alcohol consumption in rodent models. Phase 3 trials are being designed.

Early evidence is promising but less developed than the alcohol data. Animal studies consistently show GLP-1 reduces nicotine self-administration and nicotine-seeking behavior in rodents. Human observational data: multiple analyses of insurance claims and EHR data have shown that GLP-1 users have higher smoking cessation rates than non-GLP-1 users, independent of other factors. However, these are observational studies subject to confounding — patients who lose weight may be more health-motivated across multiple behaviors. Randomized controlled trials specifically targeting nicotine use disorder with GLP-1 medications are in early stages. Current status: promising preclinical and observational signal; no RCT confirmation yet. GLP-1 medications are not currently indicated for smoking cessation.

The evidence for GLP-1 in opioid use disorder (OUD) is the earliest-stage of the three substance areas. Animal studies show GLP-1 receptor activation reduces opioid self-administration and withdrawal behaviors in rodents. Human epidemiological data is limited. The mechanistic rationale is similar: opioid reward involves dopaminergic signaling in the nucleus accumbens, and GLP-1 modulates this pathway. However, opioid reward circuitry is more complex and involves mu-opioid receptors in ways that may make GLP-1's partial modulation less effective than for alcohol or food. Phase 2 trials in OUD are being planned or are in early recruitment. Current recommendation: GLP-1 should not substitute for established OUD treatments (buprenorphine, methadone, naltrexone). Any potential GLP-1 contribution to OUD would be adjunctive.

GLP-1 receptors are expressed throughout the brain's reward circuitry: nucleus accumbens (NAc), ventral tegmental area (VTA), prefrontal cortex, and amygdala — collectively the mesolimbic and mesocortical dopamine systems. These are the same circuits that mediate all reward — food, alcohol, nicotine, opioids, gambling. GLP-1 signaling in the NAc reduces dopamine release in response to reward stimuli. The result: the reward value of the substance (or food) is blunted — patients report less craving, less pleasure from the behavior, and reduced compulsive seeking. This is mechanistically analogous to how GLP-1 reduces 'food noise' — the constant intrusive food thoughts that patients describe before treatment. The same signal dampening applies to other reward stimuli.

As of April 2026, GLP-1 medications are not FDA-approved for alcohol use disorder. ATTAIN-1 is a Phase 2 trial — the standard requires Phase 3 confirmation before approval. Off-label use for AUD in patients who also qualify for GLP-1 on obesity/metabolic grounds is clinically defensible based on available evidence, but this should be a shared decision with a provider who is aware of both the AUD and the metabolic indication. Patients with AUD who do not have obesity or type 2 diabetes should not use GLP-1 for AUD outside of clinical trial settings. Established evidence-based AUD treatments (naltrexone, acamprosate, buprenorphine for comorbid OUD, behavioral therapy) should not be deferred in favor of GLP-1 while awaiting Phase 3 data.

In-Depth Guide

GLP-1 Medications and Addiction: The Reward Circuit Connection

The same neural mechanism that causes GLP-1 to reduce food cravings appears to reduce the reward drive for alcohol, nicotine, and potentially opioids — with a rapidly growing evidence base.

The Shared Reward Circuit

The mesolimbic dopamine system (nucleus accumbens → VTA) underlies all reward:

Reward Type	Dopamine Signal	GLP-1 Effect on NAc
Food (palatable)	Strong dopamine release	Blunted — "food noise" reduction
Alcohol	Dopaminergic activation	Blunted — ATTAIN-1 data
Nicotine	Strong dopaminergic activation	Blunted — animal models, observational human data
Opioids	Mu-opioid + dopaminergic	Partially blunted — animal models
Gambling/behavioral	Variable dopaminergic	Theoretical; no trials

GLP-1 acts as a "volume dial" for reward sensitivity — not eliminating reward signaling, but reducing its compulsive intensity.

Evidence Status by Substance

Substance	Preclinical Evidence	Human RCT Evidence	Current Status
Alcohol	Strong — consistent across species	ATTAIN-1 Phase 2 (positive)	Phase 3 trials being designed
Nicotine	Strong — multiple rodent models	Observational only	Phase 2 trials early stage
Opioids	Moderate — some models	Epidemiological signals	Phase 2 planned
Stimulants (cocaine, meth)	Moderate	None	Preclinical stage
Cannabis	Limited	None	Hypothesis only

ATTAIN-1 Summary

Parameter	Semaglutide	Placebo
Heavy drinking days per week	Significantly reduced	Minimal change
Total alcohol consumption	Significantly reduced	Minimal change
Side effect profile	GI (typical for semaglutide)	Minimal
Treatment duration	16 weeks	16 weeks

Phase 2 trial — results require Phase 3 confirmation for clinical guideline incorporation.

Clinical Implications: Who Might Benefit Now

Patient Type	GLP-1 + Addiction Clinical Context
Obesity + AUD (both conditions meet criteria)	GLP-1 for obesity — AUD reduction may be an additional benefit
Obesity + heavy drinking below AUD threshold	GLP-1 for obesity — alcohol reduction is a favorable secondary effect
AUD without obesity/T2DM	No current approved indication — trial enrollment if interested
Nicotine use + obesity	GLP-1 for obesity — smoking cessation benefit plausible but not confirmed

GLP-1 Cravings Alcohol FAQ — alcohol cravings and GLP-1 mechanisms
GLP-1 Food Noise FAQ — the shared mechanism with addiction reduction
GLP-1 Mental Health FAQ — depression, anxiety, and GLP-1
GLP-1 Cognitive Brain FAQ — GLP-1 receptors throughout the brain

More GLP-1 FAQs

Explore other common questions about GLP-1 medications

Ready to Find Your Provider?

Take our quiz to get personalized provider recommendations based on your needs.

Find Your Match Compare Medications

GLP-1 Medications and Addiction: Alcohol, Nicotine, and Opioid Use Disorder Research

Quick Answers

In-Depth Guide

GLP-1 Medications and Addiction: The Reward Circuit Connection

The Shared Reward Circuit

Evidence Status by Substance

ATTAIN-1 Summary

Clinical Implications: Who Might Benefit Now

Related Resources

More GLP-1 FAQs

Compounded vs Brand-Name GLP-1 FAQ: Safety, Legality, and Key Differences

GLP-1 Medications and ADHD: Dopamine Overlap, Stimulant Interactions, and Appetite Effects

GLP-1 and Alcohol: Can You Drink on Semaglutide or Tirzepatide?

GLP-1 Medications and Appetite Suppression: When It's Too Much

GLP-1 Medications and Athletic Performance: What Athletes and Active Patients Need to Know

GLP-1 vs Bariatric Surgery: Efficacy, Risks, Cost, and Who Should Choose Which

GLP-1 Medications and Birth Control: What You Need to Know

Body Recomposition on GLP-1: Losing Fat While Preserving Muscle

Cagrisema: The GLP-1 + Amylin Combination That May Surpass Tirzepatide

GLP-1 Medications and Cardiovascular Risk: Beyond the SELECT Trial

GLP-1 Medications for Adolescents: FDA Approval, Safety, and What Parents Need to Know

GLP-1 Medications and Brain Health: Cognition, Dementia Risk, and Neurological Effects

Compounding Pharmacies for GLP-1 Medications: 503A vs 503B, Safety, and Legal Status

Compounded GLP-1 Status April 2026: What's Legal, What's Not, and What Changed

GLP-1 Medications and Constipation: Causes and Relief

Is GLP-1 Worth the Cost? Cost-Effectiveness Explained

GLP-1 Cost & Insurance FAQ: What You'll Actually Pay for Semaglutide, Tirzepatide & More

GLP-1 Medications and Alcohol Cravings: What the Research Shows

Can You Get Semaglutide at CVS or Walgreens? GLP-1 Pharmacy FAQ

GLP-1 Medications and Dental Health: Dry Mouth, 'Ozempic Mouth,' and Oral Care

GLP-1 for Diabetes vs Weight Loss: Key Differences Explained

What to Eat (and Avoid) on Semaglutide — Diet FAQ

GLP-1 Dosing Schedule: When and How to Take Your Medication

GLP-1 Medication Drug Interactions: What to Watch For

GLP-1 Eligibility & Access FAQ: Do You Qualify for Semaglutide or Tirzepatide?

Can I Get a GLP-1 Prescription? BMI and Eligibility FAQ

Exercise on GLP-1 Medications: What to Do, When to Start, and How Much

GLP-1 Medications and Fatty Liver Disease (MASH/NAFLD): What to Know

First Week on GLP-1: What to Expect (Day by Day)

Food Noise and GLP-1 Medications: What It Is and Why It Goes Quiet

GLP-1 Medications for PCOS: Benefits, Evidence, and What to Expect

GLP-1 for Specific Conditions: PCOS, Type 2 Diabetes, Metabolic Syndrome & More

GLP-1 Medications and Gallbladder: Gallstone Risk FAQ

GLP-1 Medications and Gout: Uric Acid, Flares, and What to Expect

GLP-1 Medications and the Gut Microbiome: What the Research Shows

Does Semaglutide Cause Hair Loss? GLP-1 and Hair Loss FAQ

Headaches on GLP-1 Medications: Causes, Duration, and What Helps

GLP-1 Medications and Heart Disease: Benefits and Considerations

GLP-1 Medications and Heart Failure: STEP-HFpEF Results and What They Mean

GLP-1 Medications and Hidradenitis Suppurativa: Inflammation, Obesity, and Emerging Evidence

GLP-1 Medications and Hypoglycemia: Who Is at Risk and What to Do

GLP-1 Medications and Systemic Inflammation: Beyond Weight Loss

GLP-1 Injection Sites: Where to Inject, How to Rotate, and What to Avoid

How to Inject Semaglutide: Step-by-Step Guide and FAQ

GLP-1 Insurance Denial: How to Appeal and Get Coverage

GLP-1 Prior Authorization: How to Get Your Insurance to Cover Ozempic or Wegovy

GLP-1 Medications and Joint Pain: What Weight Loss Does to Arthritis and Joints

GLP-1 Medications and Kidney Disease: What Patients Need to Know

Lab Tests Before and During GLP-1 Medication Treatment

GLP-1 Long-Term Safety: What We Know After 5+ Years of Data

GLP-1 Maintenance Dose: What Happens After You Reach Your Goal

GLP-1 Medications and Male Fertility: Sperm Quality, Testosterone, and What Men Should Know

GLP-1 Medication Storage: Temperature, Cold Chain, and What to Do If Your Pen Gets Warm

GLP-1 Medications Compared: Semaglutide vs Tirzepatide vs Liraglutide vs Orforglipron

GLP-1 Medications and Testosterone in Men: What the Evidence Shows

GLP-1 Medications During Menopause and Perimenopause: What Changes

GLP-1 Medications and Mental Health: Mood, Depression, and Anxiety

GLP-1 Medications and Metabolic Syndrome: Addressing All Five Criteria

GLP-1 Medications and Muscle Loss: What the Research Shows

GLP-1 Nausea: How to Manage It and When It Goes Away

GLP-1 Injections and Needle Phobia: How to Manage Fear and What Alternatives Exist

GLP-1 Non-Responders: Why Some People Don't Lose Weight and What to Do

GLP-1 and Obesity as a Disease: Why It's Not About Willpower

GLP-1 Medications for Adults Over 65: Benefits, Risks, and Special Considerations

Orforglipron: The First True Oral GLP-1 Pill Without Special Handling

GLP-1 Medications and Pancreatitis: Risk FAQ

GLP-1 Patient Advocacy Guide: Getting Your Prescription, Fighting Denials, and Talking to Your Doctor

GLP-1 Pen vs Vial: Brand-Name vs Compounded Delivery Compared

GLP-1 Weight Loss Plateau: Why It Happens and What To Do

GLP-1 Medications During Pregnancy and Breastfeeding: What You Need to Know